TFO Wealth Partners’s Clearside Biomedical CLSD Stock Holding History

TFO Wealth Partners’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6	Closed	–	–	159
2020 Q2	$0	Hold	6	–	–	﹤0.01%	134
2020 Q1	$0	Hold	6	–	–	﹤0.01%	134
2019 Q4	$0	Buy	+6	New	+$126	﹤0.01%	140

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TFO Wealth Partners's CLSD Position: Q3 2020 in Review

TFO Wealth Partners sold out of Clearside Biomedical (CLSD) in Q3 2020, closing a stake of 6 shares.

TFO Wealth Partners first reported a position in CLSD in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 41 funds tracked by Wall St. Rank hold CLSD as of Q3 2020.

TFO Wealth Partners reported no remaining Clearside Biomedical position as of Q3 2020 after selling out during the quarter.
TFO Wealth Partners sold 6 Clearside Biomedical shares in Q3 2020.
TFO Wealth Partners first reported a position in Clearside Biomedical in Q4 2019 and held it in 3 quarters.
TFO Wealth Partners's Clearside Biomedical position peaked at $0 in Q2 2020.
41 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2020.

Based on TFO Wealth Partners's 13F filing for Q3 2020, filed 14 Oct 2020.